Urinary cell TWIST1 methylation as a non-invasive dual biomarker: A Multicenter study for early detection and recurrence monitoring in bladder cancer.
A urine test detecting a specific methylation pattern identified bladder cancer with high accuracy, offering a less invasive screening option than traditional methods.
This multicenter diagnostic validation study evaluated To develop and validate a non-invasive urine-based TWIST1 methylation-specific quantitative methylation‑specific polymerase chain reaction (qMSP) assay for bladder cancer (BC) diagnosis and surveillance to address the clinical need for a reliable complement invasive cystoscopy. The authors report that in an independent multicenter cohort of 1,233 participants, urinary TWIST1 methylation detected primary bladder cancer with 88,2% sensitivity and 86,8% specificity.
What the study was
- Study design
- Multicenter diagnostic validation study
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Cancer genetics
Why it surfaced
9/10: Multicenter diagnostic validation study with direct relevance to Early cancer detection; scoring remains conservative because triage used the PubMed abstract without full-text review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.